No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
BCRX240816C9000
- 0.08
- 0.000.00%
15min DelayClose Jul 22 15:49 ET
0.10High0.05Low
0.10Open0.08Pre Close16 Volume117 Open Interest9.00Strike Price110.00Turnover61.35%IV22.37%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier24DDays to Expiry0.08Extrinsic Value100Contract SizeAmericanOptions Type0.1342Delta0.1825Gamma98.93Leverage Ratio-0.0053Theta0.0006Rho13.28Eff Leverage0.0042Vega
Intraday
- 5D
- Daily
News
BioCryst to Report Second Quarter 2024 Financial Results on August 5
United States Hereditary Angioedema Therapeutics Market Report 2024: Trends, Dynamics, Competition, Forecast and & Opportunities, 2019-2029F - ResearchAndMarkets.com
BioCryst Pharmaceuticals' (NASDAQ:BCRX) Growing Losses Don't Faze Investors as the Stock Spikes 18% This Past Week
There's No Escaping BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Muted Revenues
BofA Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $11
Pint Pharma Announces the Approval of ORLADEYO (Berotralstat), the First Oral Therapy Indicated to Prevent Hereditary Angioedema (HAE) Attacks in Adults and Children 12 Years and Older in Peru.
Comments
$BioCryst Pharmaceuticals(BCRX.US$ Reuters · 1 min ago BioCryst Pharmaceuticals- Orladeyo® (Berotralstat) Approved in Peru
$BioCryst Pharmaceuticals(BCRX.US$ Director ASELAGE STEVE purchased 2,500 shares of common stock on May 24, 2024 at an average price of $6.4 for a total value of $16,000.
1
$BioCryst Pharmaceuticals(BCRX.US$ Benzinga· 1 min BioCryst Presents New Real-world Evidence Showing Significant Reductions In Healthcare Resource Utilization Among Patients With Hereditary Angioedema Following Initiation Of Orladeyo (Berotralstat
1
2
$BioCryst Pharmaceuticals(BCRX.US$ BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update
—Q1 2024 ORLADEYO net revenue grows 30 percent y-o-y to $88.9 million—
—Full-year 2024 ORLADEYO revenue guidance adjusted to $390-$400 million (top end of prior guidance range) —
—Pipeline programs, including BCX17725 for Netherton syndrome and avoralstat for DME, advancing on schedule into clinical trials—
—Q1 2024 ORLADEYO net revenue grows 30 percent y-o-y to $88.9 million—
—Full-year 2024 ORLADEYO revenue guidance adjusted to $390-$400 million (top end of prior guidance range) —
—Pipeline programs, including BCX17725 for Netherton syndrome and avoralstat for DME, advancing on schedule into clinical trials—
2
Read more